AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The approval is backed by data showing deep, durable responses and manageable tolerability
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Syrma Johari is a globally recognised medical device engineering and manufacturing organisation
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
Subscribe To Our Newsletter & Stay Updated
